Seres Therapeutics Reports Ser-155 Phase 1B Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)
seres therapeutics報告了ser-155第10億安慰劑對照隊列2研究的安全性和臨床結果,該研究針對進行異體造血幹細胞移植(Allo-Hsct)的患者